文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗再照射治疗盆腔淋巴结寡复发前列腺癌:CYGNUS多中心回顾性研究

Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-03-19

CYGNUS多中心回顾性研究评估立体定向体部放疗(SBRT)再照射治疗既往照射区域内盆腔淋巴结寡复发(PNMOR)激素敏感性前列腺癌的毒性和疗效。150例患者共155次再照射,中位随访30.5个月,晚期2级胃肠和泌尿生殖毒性分别为1.9%和7.1%,3级分别为0%和2.6%;2年影像学无进展生存率44.6%,2年无雄激素剥夺治疗(ADT)生存率52.6%。既往ADT使用和PSA倍增时间<5个月与较差结局相关。

要点

  • SBRT再照射治疗PNMOR的晚期2级胃肠和泌尿生殖毒性分别为1.9%和7.1%,3级分别为0%和2.6%。
  • 2年影像学无进展生存率44.6%,2年无ADT生存率52.6%。
  • 既往ADT使用和PSA倍增时间<5个月与较差生存结局相关。

核心结论

  • CYGNUS回顾性研究提示SBRT再照射治疗PNMOR与低毒性率相关,但需计划叠加和更长随访数据确认。

研究设计与样本

  • 多中心回顾性研究纳入150例既往根治性治疗后生化复发、影像学怀疑PNMOR(盆腔淋巴结区≤5个可疑淋巴结)的患者,共155次再照射,来自13个法国中心。

主要发现

  • 中位随访30.5个月,晚期2级胃肠和泌尿生殖毒性分别为1.9%和7.1%,3级分别为0%和2.6%。
  • 2年影像学无进展生存率44.6%(95% CI, 36.2%-55%),2年无ADT生存率52.6%(95% CI, 42%-65.9%)。
  • 多变量分析中既往ADT使用预测影像学无进展生存(HR, 2.02; 95% CI, 1.25-3.26; P = .004)和无ADT生存(HR, 2.49; 95% CI, 1.28-4.72; P = .006)。
  • PSA倍增时间<5个月与较短的无ADT生存相关(AUC, 0.629; P = .014)。

关键数值与推荐

  • 再照射定义为与既往放疗疗程有几何重叠的照射,依据ESTRO-EORTC再照射共识。
  • 生化复发定义依据欧洲泌尿外科学会(EAU)指南。
  • PNMOR定义为盆腔淋巴结区复发且可疑淋巴结≤5个。

临床怎么用

  • 对既往照射区域内盆腔淋巴结寡复发激素敏感性前列腺癌,SBRT再照射可作为 Salvage 选择,毒性较低。
  • 既往ADT使用和PSA倍增时间<5个月提示再照射后结局较差,需个体化评估。

局限性

  • 回顾性研究设计。
  • 缺乏计划叠加剂量信息。
  • 随访时间较短,需更长随访确认 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CYGNUS study aims to assess both toxicity and efficacy of stereotactic body radiation therapy performed as salvage approach for pelvic nodal metachronous oligorecurrent (PNMOR) hormone-sensitive prostate cancer, in previously irradiated territory. METHODS AND MATERIALS: Inclusion criteria were histologically history of proven prostate cancer, locally treated with a radical intent and a biochemical relapse as defined by the European Association of Urology guidelines. All patients had a radiological suspicion of PNMOR, defined as a recurrence occurring in pelvic nodal areas with up to 5 suspect lymph nodes. Reirradiation was defined according to the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer (ESTRO-EORTC) consensus on reirradiation as an irradiation with a geometric overlap with a previous course of radiation therapy. RESULTS: A total of 155 reirradiation among 150 patients relapsing on 192 nodal sites were retrospectively included, from 13 French centers. The majority of patients (80.7%) received radical prostatectomy as primary treatment. After a median follow-up of 30.5 months, late grade 2 and grade 3 gastrointestinal and genitourinary toxicity occurred in 1.9%, 0%, and 7.1%, and 2.6% of the cases, respectively. The 2-year radiological progression-free survival reached respectively 44.6% (95% CI, 36.2%-55%). The 2-year androgen deprivation therapy-free survival (ADT-FS) reached 52.6% (95% CI, 42%-65.9%). Previous ADT prescription was predictive in multivariable analysis of both radiological progression-free survival (hazard ratio, 2.02; 95% CI, 1.25-3.26; P = .004) and ADT-FS (hazard ratio, 2.49; 95% CI, 1.28-4.72; P = .006). A prostate-specific antigen doubling time <5 months correlated with a shorter ADT-FS (area under the curve, 0.629; P = .014). CONCLUSIONS: The CYGNUS retrospective study suggests that reirradiation with stereotactic body radiation therapy for PNMOR is associated with a low rate of toxicity. However, further data with plan summation and longer follow-up are needed to confirm these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Anger E, Supiot S, Josset Q, et al. Pushing the Boundaries of Stereotactic Body Radiation Therapy in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 41864432. doi:10.1016/j.ijrobp.2026.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。